How to take Pexidartinib

The recommended dose of pexidartinib for the treatment of tenosynovial giant cell tumor (TGCT) is 400 mg twice daily on an empty stomach (at least one hour before or two hours after a meal) until disease progression or unacceptable toxicity occurs. If a patient develops an adverse reaction after taking Pesidartinib, the doctor will adjust the dose of Pesidartinib (reduce, interrupt or stop the administration) based on the severity of the adverse reaction. The first dose reduction of pexidartinib was 200 mg in the morning and 400 mg in the evening; the second dose was reduced to 200 mg twice daily.

Patients who cannot tolerate 200 mg taken orally twice daily should permanently discontinue pexidartinib. Avoid concomitant use of pexidartinib with moderate or severe CYP3A inhibitors or UGT inhibitors. If unavoidable, reduce to 200 mg for patients taking 400 mg orally twice daily; for patients taking 600 mg orally twice daily, reduce to 200 mg twice daily; for patients taking 200 mg orally twice daily, reduce to 200 mg once daily. The recommended dose of pexidartinib in patients with mild to severe renal impairment ([CLcr] 15-89 mL/min) is 200 mg in the morning and 400 mg in the evening. The recommended dose of pexidartinib for patients with moderate hepatic impairment (total bilirubin greater than 1.5, up to 3 times the upper limit of normal (ULN), not due to Gilbert syndrome, and associated with any AST) is 200 mg twice daily.

Pesidartinib is not marketed in the country. There is less information on the price and other related information of pexidartinib after it is launched overseas. For more drug information and specific prices, please consult the medical consultant.